$ACOG.v Appoints New CFO As Alpha Cognition (TSXV: ACOG) enters its next phase of growth, the company has appointed Don Kalkofen as CFO. Don has considerable experience in corporate finance, as well as a strong track record of successfully supporting the financing of clinical-stage biotech company development.
https://financialpost.com/pmn/press-releases-pmn/business-wire-news-releases-pmn/alpha-cognition-announces-change-of-cfo-grant-of-stock-options-and-addition-to-the-board-of-directors
With $ACOG.v working towards clinical trials for its ALPHA-0602 gene therapy, funding acquisition will be crucial going forward. I expect this appointment should lead to some promising updates from the company in the future.
Shares of $ACOG.v have been bouncing around an 18% price range since February, and are currently trading at $.93. The company is currently valued at $57.19M.